Short
Celyad Oncology SA
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1560 EUR
−5.82 M EUR
186.00 K EUR
42.05 M
About Celyad Oncology SA
Sector
Industry
CEO
Matthew R. Kane
Website
Headquarters
Mont-Saint-Guibert
Founded
2007
IPO date
Jul 5, 2013
Identifiers
2
ISIN BE0974260896
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Related stocks
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CYAD is 0.2210 EUR — it has increased by 10.00% in the past 24 hours. Watch Celyad Oncology SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Celyad Oncology SA stocks are traded under the ticker CYAD.
CYAD stock has risen by 29.41% compared to the previous week, the month change is a 29.41% rise, over the last year Celyad Oncology SA has showed a −47.63% decrease.
CYAD reached its all-time high on May 25, 2015 with the price of 70.9500 EUR, and its all-time low was 0.1600 EUR and was reached on Dec 30, 2025. View more price dynamics on CYAD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYAD stock is 18.96% volatile and has beta coefficient of −0.15. Track Celyad Oncology SA stock price on the chart and check out the list of the most volatile stocks — is Celyad Oncology SA there?
Today Celyad Oncology SA has the market capitalization of 8.95 M, it has increased by 8.82% over the last week.
Yes, you can track Celyad Oncology SA financials in yearly and quarterly reports right on TradingView.
Celyad Oncology SA is going to release the next earnings report on Mar 19, 2026. Keep track of upcoming events with our Earnings Calendar.
CYAD net income for the last half-year is −3.67 M EUR, while the previous report showed −2.78 M EUR of net income which accounts for −32.24% change. Track more Celyad Oncology SA financial stats to get the full picture.
No, CYAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 12, 2026, the company has 15 employees. See our rating of the largest employees — is Celyad Oncology SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celyad Oncology SA EBITDA is −6.32 M EUR, and current EBITDA margin is −3.12 K%. See more stats in Celyad Oncology SA financial statements.
Like other stocks, CYAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celyad Oncology SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Celyad Oncology SA technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Celyad Oncology SA stock shows the sell signal. See more of Celyad Oncology SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.